Forward Pharma A Stock Working Capital
| FWPDelisted Stock | USD 2.56 0.00 0.00% |
Forward Pharma A fundamentals help investors to digest information that contributes to Forward Pharma's financial success or failures. It also enables traders to predict the movement of Forward Stock. The fundamental analysis module provides a way to measure Forward Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Forward Pharma stock.
Forward |
Forward Pharma A Company Working Capital Analysis
Forward Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Forward Pharma Working Capital | 93.59 M |
Most of Forward Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Forward Pharma A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Forward Pharma A has a Working Capital of 93.59 M. This is 78.01% lower than that of the Biotechnology sector and 82.62% lower than that of the Health Care industry. The working capital for all United States stocks is 93.67% higher than that of the company.
Forward Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forward Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forward Pharma could also be used in its relative valuation, which is a method of valuing Forward Pharma by comparing valuation metrics of similar companies.Forward Pharma is currently under evaluation in working capital category among its peers.
Forward Fundamentals
| Return On Equity | -0.0083 | |||
| Return On Asset | -0.0342 | |||
| Current Valuation | (43.04 M) | |||
| Shares Outstanding | 7.09 M | |||
| Shares Owned By Institutions | 12.90 % | |||
| Number Of Shares Shorted | 4.51 K | |||
| Price To Earning | 0.13 X | |||
| Price To Book | 0.31 X | |||
| EBITDA | (1.89 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 70.77 M | |||
| Cash Per Share | 10.08 X | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 117.44 X | |||
| Book Value Per Share | 8.76 X | |||
| Cash Flow From Operations | (2.36 M) | |||
| Short Ratio | 1.78 X | |||
| Earnings Per Share | (0.27) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 37.0 | |||
| Beta | 1.38 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 71.41 M | |||
| Retained Earnings | (9.1 M) | |||
| Working Capital | 93.59 M | |||
| Current Asset | 99.8 M | |||
| Current Liabilities | 6.21 M | |||
| Z Score | 1.2 | |||
| Net Asset | 71.41 M |
About Forward Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Forward Pharma A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forward Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forward Pharma A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Forward Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Forward Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Forward Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Forward Stock
| 0.57 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.56 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.52 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.49 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.36 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
The ability to find closely correlated positions to Forward Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Forward Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Forward Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Forward Pharma A to buy it.
The correlation of Forward Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Forward Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Forward Pharma A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Forward Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Forward Stock
If you are still planning to invest in Forward Pharma A check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Forward Pharma's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |